

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

**10/069673**

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/NL00/00596

August 28, 2000

September 3, 1999

**TITLE OF INVENTION VETERINARY FORMULATIN FOR ADMINISTRATION OF A WATER-INSOLUBLE  
DRUG TO A TARGET ANIMAL THROUGH A WATER DISTRIBUTION SYSTEM**

APPLICANT(S) FOR DO/EO/US

JANSSEN PHARMACEUTICA N.V.:

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.  
PCT/NL00/00596

J013 Rec'd PCT/PTO 22 FEB 2002

ATTORNEY'S DOCKET NUMBER  
JAB-1525 PCT

10/069673

17. The following fees are submitted:  
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO..... \$1040.00International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO..... \$890.00International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but international search fee (37 CFR 1.455(a)(2)) paid to USPTO..... \$740.00International preliminary examination fee (37 CFR 1.482) paid to  
USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$750.00International preliminary examination fee (37 CFR 1.482) paid to  
USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)). \$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	10 - 20 =	0	x \$18.00	\$
Independent claims	2 - 20 =	0	x \$84.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$

TOTAL OF ABOVE CALCULATIONS = \$890.00

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement  
must also be filed (Note 37 CFR 1.9, 1.27, 1.28). \$

SUBTOTAL = \$890.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)). \$

TOTAL NATIONAL FEE = \$890.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 40.00

TOTAL FEES ENCLOSED = \$930.00

Amount to be refunded:	\$
charged:	\$

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 10-0750/JAB-1525/ECC in the amount of \$930.00 to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 10-0750/JAB-1525/ECC. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or  
(b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Philip S. Johnson, Esq.  
Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
USA

Signature

Ellen Ciabrone Coletti  
Reg. No. 34,140  
Attorney for Applicants

100610/06967302

JC13 Rec'd PCT/PTO 22 FEB 2002

DOCKET NO. JAB-1525

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter F. Ekhart, Mario Van Wandelen and Jan M. Jetten

For : VETERINARY FORMULATION FOR ADMINISTRATION OF A  
WATER-INSOLUBLE DRUG TO A TARGET ANIMAL THROUGH A  
WATER DISTRIBUTION SYSTEM

Express Mail Certificate

"Express Mail" mailing number: EV065839607US

Date of Deposit: February 22, 2002

I hereby certify that this entry into the National Phase pursuant to 35 USC 371 with a copy of PCT Application PCT/NL00/00596 filed August 28, 2000, including From PTO 1390, Declaration and Power of Attorney, Preliminary Amendment, Information Disclosure Statement with PTO Form 1449 along with copies of cited art, and copy of International Search Report, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Diane Hetzler

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

JC13 Rec'd PCT/PTO 22 FEB 2002

Docket No. JAB-1525

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peter F. Ekhart et al.  
Serial No. :  
Filed :  
Title : VETERINARY FORMULATION FOR ADMINISTRATION OF A  
WATER-INSOLUBLE DRUG TO A TARGET ANIMAL THROUGH A  
WATER DISTRIBUTION SYSTEM

Art Unit :  
Examiner :

Honorable Commissioner of Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Dear Sir:

Prior to examination, please amend the above-identified application as follows:

**In the Specification:**

Page 1, between the Title and line 4, please insert the following:

-- Cross Reference to Related Applications

This application is the national stage of Application No. PCT/NL00/00596, filed August 28, 2000 which application claims priority from EP 99202876.1, filed September 3, 1999. —

**In the Claims:**

4. (Amended) A method according to claim 1, in which the active compound and the water-immiscible liquid are used in a weight ratio between 10:90 and 75:25.
5. (Amended) A method according to claim 1, in which either the active compound or the water-immiscible liquid has a lower density than water and the other has a higher density than water.

Serial No. 10/000,000

6. (Amended) A method according to claim 1, in which said mixture or the suspension thereof in the aqueous carrier comprises one or more stabilising agents belonging to the group of emulsifiers, surfactants, thickeners, anti-oxidants and anti-microbials.
7. (Amended) A method according to claim 1, in which said water-immiscible liquid is a vegetable oil.
8. (Amended) A method according to claim 1, in which the average particle size of the active compound is between 1 and 30  $\mu\text{m}$ .

Serial No. 10/000,000

**REMARKS/ARGUMENTS**

Consideration of the captioned application in view of the foregoing amendments and following remarks is requested.

The specification has been amended to refer to the priority applications.

Claims 1-10 remain in this application. Claims 4-8 have been amended.


Enclosed herewith is an Information Disclosure Statement with a copy of the International Search Report and documents cited therein.

Early favorable action on the merits is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made".

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By:   
Ellen Ciambrone Coletti  
Reg. No. 34,140

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2359  
Dated: 2.22.02

Serial No. 10/000,000

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Page 1, between the Title and line 4, please insert the following:

-- Cross Reference to Related Applications

This application is the national stage of Application No. PCT/NL00/00596, filed August 28, 2000 which application claims priority from EP 99202876.1, filed September 3, 1999. –

**In the Claims:**

4. (Amended) A method according to [any one of ] claim[s] 1[-3], in which the active compound and the water-immiscible liquid are used in a weight ratio between 10:90 and 75:25.
5. (Amended) A method according to [any one of] claim[s] 1[-4], in which either the active compound or the water-immiscible liquid has a lower density than water and the other has a higher density than water.
6. (Amended) A method according to [any one of] claim[s] 1[-5], in which said mixture or the suspension thereof in the aqueous carrier comprises one or more stabilising agents belonging to the group of emulsifiers, surfactants, thickeners, anti-oxidants and anti-microbials.
7. (Amended) A method according to [any one of] claim[s] 1[-6], in which said water-immiscible liquid is a vegetable oil.
8. (Amended) A method according to [any one of] claim[s] 1[-7], in which the average particle size of the active compound is between 1 and 30  $\mu\text{m}$ .

**Veterinary formulation for administration of a water-insoluble drug to a target animal through a water distribution system**

[0001] The present invention relates to a method for preparing a veterinary composition comprising a water-insoluble veterinary active compound, especially a benzimidazole anthelmintic, suitable for administering to a target animal through a water distribution system for the purpose of therapeutic and prophylactic medication.

***Background of the invention***

[0002] Parasitic infections continue to be an important problem in animal production.. Prophylactic or therapeutic use of anthelmintic drugs is a standard practice for every farm, where pigs or all kinds of poultry species are reared. The requirements for an anthelmintic product that is suitable for use in the intensive pig and poultry industry are: a broad spectrum activity (active against all important worm species that can occur in pigs), potent activity against the adult as well as the larval stages of the worms and the products should also have a wide safety margin.

[0003] For pig production 3 main groups of products are used:

\* imidathiazoles (levamisole).

\* avermectins (ivermectin, doramectin, ...).

\* benzimidazoles (flubendazole, fenbendazole, mebendazole, oxfendazole, albendazole, cambendazole, parbendazole, oxbendazole and cyclobendazole), and pro-benzimidazoles (febantel, thiophanate and netobimin).

[0004] For the poultry industry the avermectins are excluded because of specific toxicity reasons and the choice is therefore largely limited to levamisole and a few benzimidazole compounds.

[0005] The administration of benzimidazole compounds to pigs and poultry has so far been limited to oral administration as a top dressing on the feed or admixed into the feed. Benzimidazoles are insoluble in water and therefore their administration via the drinking water has been virtually impossible.

[0006] Medication via drinking water is routinely used for prophylaxis and treatment of infectious diseases of intensively reared animals. The increased flexibility offered by medicating via water as compared to either parenteral or in-feed medication makes it an attractive alternative.

[0007] With drinking water treatment the major drawbacks of in-feed medication can be



avoided:

- medicated feed may not be immediately available when animals are sick
  - poor homogeneity of mix
  - segregation from feed during transport
  - 5 • variable individual intake
  - requires bulk storage
  - cross contamination (carry-over) of feed batches at the feed mill
  - difficult to manage withdrawal times
  - no flexibility in treatment and dosage schedules
  - 10 • sick animals stop eating and therefore stop taking the necessary mounts of medication.
- [0008] The effectiveness of medication via the drinking water largely depends on the quality of the formulation and the palatability of the medication. Such formulation should provide:
- maximum availability of the drug
  - minimal segregation of the active compound in the water delivery systems, medication
  - 15 pumps, nipples, cups... etc.
  - a very precise dosing and homogeneous distribution in the water
  - a guaranteed stability of the active compound, irrespective of the quality of the water used.

- [0009] Many pig and poultry farms are already equipped with the necessary devices to
- 20 administer the medication via drinking water. Such water delivery systems on farms are complex systems of tanks, pipes, coils, pen drinkers and nipples. An average stable may contain several hundreds of metres of pipes with many coils and hundreds of individual cups and/or nipples. The water in the watering system in a pig or poultry house obeys the principles of laminar flow through the pipes and coils and is subjected to the so called "shearing" forces
- 25 which will affect the rate of flow. In such complex piping system there are considerable risks for segregation or sedimentation of the medication, certainly when it concerns water insoluble compounds.

- [0010] The quality of the drinking water will vary considerably from region to region, some farmers even might use their own water supplies. This can have a very significant impact on
- 30 the solubility or dispersibility of the medication into the drinking water.

[0011] Some products currently used in the drinking water (e.g. oxytetracycline) are not very readily soluble and solubility enhancing agents such as citric acid are often used to increase the solubility. It is known however that the use of citrate-based compounds may dislodge sediment and result in blocked nipples or drinkers. Low solubility with amoxicillin for example can

result in a homogenous lump of powder floating unused in the main header tank or leading to blockage of water proportioners (L. Reeve - Lolinson, *The Pig Journal* 1998, 42, 74-86).

[0012] Research work has demonstrated that for the administration of benzimidazole compounds via the drinking water a very robust carrier system has to be used. The invention described hereafter demonstrates that a "Solid in Oil in Water" emulsion with specifically selected excipients provides an excellent carrier for the presented problem.

[0013] Normally, water insoluble veterinary drugs are administered in dry form through one of the following routes:

- mixed into a dry feed blend, pelletised or not, and subsequently fed to the target animals of interest as a medicated feed
- mixed with a special ingredient composition which may be pelletised or not as a medicated premix. This premix is dosed by the farmer on top of the normal feed supplied to the animals.

[0014] These routes for medication are becoming less popular, due to the possibility of contamination of other feed blends with the active compound in the blending and transport equipment at the production facility, usually a feed mill. Another problem related to these routes of medication is the difficulty for the end-user, normally the farmer, to control the dosage of active compound per animal. In case of medicated feeds in mash form or medicated premixes in powder form the farmer can also be exposed to the active compound, which may pose health risks.

[0015] In case of liquid dosage of water-insoluble veterinary drugs, only trivial formulations for batch wise liquid dosage are described, with a limited stability. These formulations are not suitable for a reliable and reproducible dosage in a water distribution system. The problem is the impossibility to add these insoluble active compounds directly into the drinking water supply system, without occurrence of precipitation or creaming of the active compound in the storage vessel or in the water pipes during practical time scales of 3 up to 12 hours normally used in drug administration through drinking water systems. Up to the present no convenient solution was available for this route of medication of farm animals for water insoluble veterinary drugs.

#### *Description of the invention.*

[0016] The present invention provides a solution to these problems by presenting a new formulation method, which results in a product with such characteristics that it is suitable for

administering the water insoluble active compound through the drinking water systems presently used in animal keeping and/or production facilities.

5 **[0017]** According to the invention a method is described for the preparation of a stable veterinary formulation which is suitable for controlled dosage of a water insoluble veterinary drug or a mixture of water soluble and insoluble veterinary drugs in drinking water distribution systems used in animal husbandry. The method comprises mixing the active compound with a water-immiscible liquid in such a manner that the mixture of active compound and water-immiscible liquid has a density which near to the density of water, and suspending the mixture in an aqueous carrier. The method is further characterised by the features of the appending  
10 claims. The invention also provides an emulsion which can be prepared according to this method and which is suitable for administration through the drinking water supply.

**[0018]** Through this new formulation the veterinary drug or a mixture of veterinary drugs, alternatively called "active compound" can be delivered to the target animal

- 15 - through a water tank containing the active compound, which is connected to the common or individual water dispensers which supply water to the animals, or
- through a high or low pressure water circuit with individual water nipples.

**[0019]** The active compound can be dosed into the water system of choice by means of mixing and diluting the formulation with water in the central water tank or separate storage tank. Alternatively the formulation is injected continuously into a high or low pressure ring  
20 system for water distribution, using a dosage dispenser. The formulation has a considerable storage stability up to two years and shows a surprising good "in use" stability in each type of water distribution system. In case of the water tank dosage system, the formulation with the concentrated active compound can be dosed directly in the tank to obtain the desired concentration level for medication in the water distribution system. In case of an in-line dosage  
25 system, a pre-dilution of the original formulation will stay stable in the dispenser unit and also during and after the high shear injection into the water distribution net until the final uptake by the target animal. With this new formulation no fouling and clogging of the distribution system is observed and a very constant level of active compound is measured at the outlet, which is a prerequisite for an adequate uptake by the target animals.

30 **[0020]** Other advantages of the new formulation technique for liquid dosage suspoemulsion is the simplicity and thus the low costs of preparation, the possibility to combine different active compounds in this formulation and the ease of incorporating other adjuvants (liquid or solid). Also the absence of unwanted solvents used for solubilising water insoluble active compounds like N-methylpyrrolidone [EP 427582, Crook, M.J.] is advantageous. All the

ingredients needed for preparation of the suspoemulsion, comply with the recommendations described in the note for guidance: *Development of Pharmaceuticals for Veterinary Medicinal Products in Europe* [Directive 81/852/EEC].

[0021] The suspoemulsion formulations according to the present invention can be obtained as follows: The active water insoluble compound (or the mixture of active compounds) of interest is normally available in the form of a powder with a small particle size distribution, preferably in the range between 0 and 100  $\mu\text{m}$  and more preferably with a particle size ranging about 1  $\mu\text{m}$  to about 30  $\mu\text{m}$ , especially from 4 to 20  $\mu\text{m}$ , as can be determined by the usual techniques like for example static light scattering measurements. An example of active compounds of interest are the anthelmintics, more specifically the benzimidazole derivatives, which normally show a very limited solubility in water. Their levels of administration through a water distribution system, normally range between 0.01 and 1 wt.% of active compound, which can be obtained by dilution from a concentrated suspoemulsion through the different water distribution systems described before.

[0022] In a preferred embodiment of the invention, the active compound can be suspended at a level ranging between 1 and 90 wt.% active compound, more preferably between 10 and 30 wt.%, into a suitable water immiscible liquid. The water immiscible liquid selected, normally shows a good affinity with the solid particles of the active compound, facilitating a good wettability of the solid particles. In the event of limited wettability of the active compound powder, wetting agents like for example lignosulphonates and non-ionic ethoxylates can be used. Normally these compounds are not necessary with the preferred method of formulation.

[0023] Depending on the density of the active compound, the water immiscible liquid, preferably, has a density, which compensates for the density of the active compound. This leads to a combined specific density of the solid-immiscible liquid aggregate which is, more or less, equal to the density of water (regarded to be 1000  $\text{kg/m}^3$ ). This will slow down the creaming or precipitation of the active compound during storage and usage. In case the active compound has a mean density higher than 1000  $\text{kg/m}^3$ , a water immiscible liquid with a density lower than 1000  $\text{kg/m}^3$  is preferably used. In case of an anthelmintic like Flubendazole® with a density of 1420  $\text{kg/m}^3$ , an oil can be selected like sunflower oil with a density of approximately 920  $\text{kg/m}^3$ . In case of an active compound with a density below 1000  $\text{kg/m}^3$ , an immiscible liquid with a density higher than 1000  $\text{kg/m}^3$  may be selected, like for example sucrose acetate isobutyrate, silicon oil or brominated vegetable oils. The preferred volume of water immiscible liquid needed for obtaining an overall density of 1000  $\text{kg/m}^3$  can be calculated by formula 1:

$$V_{\text{wil}} = (1000/\rho_{\text{ac}} - 1) * M_{\text{ac}} / (\rho_{\text{wil}} - 1000) \quad (1)$$

$V_{\text{wil}}$  = Volume of water immiscible liquid ( $\text{m}^3$ ) needed.

$M_{\text{ac}}$  = Mass active compound (kg).

$\rho_{\text{ac}}$  = Density of active compound ( $\text{kg}/\text{m}^3$ ).

5  $\rho_{\text{wil}}$  = Density of water immiscible liquid ( $\text{kg}/\text{m}^3$ ).

[0024] The ratio between water immiscible liquid and active compound obtained with formula 1, describing the density compensation principle, is not imperative for the choice of the actual levels used in the formula. They also depend on the practical demands stated for the commercial formulation of choice. For example, legislative, pharmaceutical or other demands and the presence of a mixture of water insoluble, active compounds could prevent the use of the density compensation principle described before. The water immiscible liquid phase could even have the same low or high density, relative to the water phase, as one or more of the selected active compounds. In this case the resulting suspoemulsion can be protected against physical destabilisation processes by using proper emulsifier and/or thickener ingredients as described later. In general a deviation from unit density from - 15% to + 20%, in particular of  $\pm 5\%$  can be accommodated, if necessary with the use of suitable emulsifiers and/or thickeners etc.

[0025] Also for the storage stability at low temperatures around 0-10 °C special precautions have to be taken, when selecting the water immiscible liquid phase, in order to prevent possible crystallisation effects of this liquid. Crystallisation would lead to a destabilisation of the suspoemulsion system. For vegetable oils, this implies that an oil containing higher levels of triglycerides with a lower chain length should be selected. For the suspoemulsion prepared, even freeze-thaw stability was observed for one freeze thaw cycle.

[0026] In order to obtain a suitable suspension of the active compound into the water immiscible liquid, several mixers can be used, for example pumps in parallel with a tank, colloid mills, high pressure homogenisers and other industrially relevant configurations.

[0027] To obtain the final formulation, in which the particles are coated with a suitable amount of the water immiscible liquid, the freshly prepared suspension is emulsified into a water phase, using a mixing device, which supplies enough energy to get the proper wetting of solid, yielding a mean specific density of the water immiscible liquid-active compound aggregate around 1000  $\text{kg}/\text{m}^3$ . For this purpose, again the same instrumental configurations as used for the preparation of the suspension can be used. In fact, the solid phase-water immiscible liquid phase is emulsified into the water phase, yielding a so called suspoemulsion [Knowles, D.A., *Chemistry and Technology of Agrochemical Formulations*, Dordrecht, Kluwer

Academic Publishers, 1998, 440p. ISBN 0-7514-0443-8]. Normally elevated energy densities are used, preferably ranging between 10-50 MJ/m<sup>3</sup>, using one or multiple stage mixing treatments. The homogenisation treatment does not cause a change in particle size distribution of the water-insoluble active compound. The ratio of solids, water-immiscible liquid and water can be chosen based on the rheological demands posed by the dosage and drinking water systems and the density compensation principle described before. Normally the formulation is optimised to the highest level of the active compound practically possible.

**[0028]** To stabilise the freshly prepared suspoemulsion against heteroflocculation and coalescence, optionally an emulsifying agent can be added, depending on the intrinsic stability of the system and the storage and "in use" stability required. For the emulsifier, a wide range of suitable ingredients and commercial mixtures of ingredients can be selected, ranging from protein products like casein or whey protein isolate and their hydrolysates, carbohydrate based emulsifiers like gum arabic or small molecules like citric acid esterified mono- or diglycerides of fatty acids. The selection of the right emulsifier depends on the exact nature of the water immiscible liquid of interest and the droplet size needed around the solid phase. Normally, the emulsifier is solubilised in the water phase or the water insoluble liquid phase before processing at the dosage levels recommended by its supplier.

**[0029]** The obtained suspoemulsion can be stabilised even better against destabilisation due to physical processes like coalescence, heteroflocculation, creaming or precipitation, by adding suitable thickeners like cross-linked polyacrylic acids, chemically modified starches or hydrocolloids like xanthan, carrageenan or other gums, propylene glycol alginate, methyl cellulose and many other commercially available thickeners. Depending on the textural needs and wants and the stability performance required for the veterinary drug formulation, the thickener or a mixture of thickeners can be selected by a skilled person. The preferred thickener in case of active compounds like anthelmintics is xanthan, giving the product a high yield stress at dosage levels preferably ranging between 0.2 and 0.4 wt% on total product, thus preventing the solid particles to flocculate, cream or precipitate under practical storage conditions.

**[0030]** Long term stability against chemical degradation can be improved if needed, by selecting a stable water immiscible liquid. In case of a vegetable oil, this implies an oil with a low content of unsaturated bonds in the fatty acid chains and high levels of anti-oxidative compounds, like tocopherols. Also anti-oxidative additives can be added to the water and/or water immiscible liquid phase in order to improve the stability of different constituents. Non-limiting examples for oxidation-limiting additives are salts of ethylenediamine-tetra-acetate (EDTA), typically at a level of 40-200ppm, e.g. 100 ppm, and citric acid (0.1-0.5% range)

which can be added to the water phase. Monoglyceride citrate (20-100 ppm range) or tocopherols, butylated hydroxytoluene and butylated hydroxyanisole (100-200 ppm range) can also be added to the water-immiscible phase prior to the processing.

- 5 [0031] Finally the stability of the veterinary drug formulation against microbial spoilage can be improved by adding anti-microbial additives to the water and/or the water immiscible phase and/or by changing the pH to the best growth-inhibiting level. Some examples of anti-microbial active compounds are parabenes, sodium benzoate and potassium sorbate, which can be dissolved in the water phase before processing at their active levels.

10 **Example 1. Preparation of a flubendazole suspoemulsion.**

- [0032] For the preparation of a veterinary drug formulation the anthelmintic flubendazole was selected as the water insoluble active compound. For the water immiscible liquid a high oleic sunflower oil (HOZOL) was selected with a melting point of 0°C. 100 grams of flubendazole were dispersed in 384 ml HOZOL oil by adding the flubendazole to the oil under stirring with an ultraturrax mixer. The water phase was prepared by making an 1 litre aqueous buffer having the following composition (dosage in wt %): Citric acid (1 wt.%), potassium sorbate (0.1 wt.%), sodium benzoate (0.1 wt.%), disodium ethylenediamine-tetra-acetate (0.01 wt.%), and 2M Sodium hydroxide solution; the pH was adjusted to 5.

- 20 [0033] 365 ml of the aqueous buffer was mixed with 150 grams of gum arabic and 2.5 grams of xanthan under stirring and this mixture was added to the oil phase containing the flubendazole, while it was stirred with an ultraturrax. The aqueous buffer was added to obtain a total volume of 1 litre of suspoemulsion with a total flubendazole content of 10 % (w/v). Finally, the crude suspoemulsion was homogenised at 500 bars by passing the preparation in three subsequent cycles through a high pressure homogeniser.

- 25 [0034] This preparation was studied for its stability under storage conditions and for "in use" situations as described in example 2.

**Example 2. Stability evaluation of the separate suspoemulsions under storage conditions and "in use" situations.**

- 30 [0035] In order to evaluate the stability of the suspoemulsion made as described under example 1, the storage stability and the "in use" stability was determined for the suspoemulsion as such and for a 0.01 wt% dilution in tap-water, based on the flubendazole content, respectively. The 0.01 wt% dilution is relevant for the diluted situation of the suspoemulsion

in the water distribution system, where it normally has an estimated residence time of maximally 3 hours.

[0036] The stability of both preparations was monitored in time by measuring destabilisation phenomena like creaming or precipitation with the help of a macroscopic optical scanning device called "Turbiscan" supplied by Formulacion, France. The 0.01 wt% flubendazole diluted suspoemulsion was measured at 0, 3 and 17 hours.

[0037] Additionally, the particle size distribution of the original suspoemulsion was determined by static light scattering measurements using a 45 mm lens and tap-water. The stability of the undiluted suspoemulsion as measured by static light scattering measurements was followed over a period of 8 months. The results from the Turbiscan scan measurements were evaluated graphically. These results show that a 10wt.% flubendazole suspension as described above exhibits no detectable destabilisation effect in comparison with a non-stabilised 10 wt.% flubendazole suspension. A 0.01 wt.% diluted suspoemulsion does not show an important creaming or precipitation effect within 17 hours, compared with a free 0.01 wt.% suspension of flubendazole respectively. This implies that the diluted product stays stable under static conditions, like for example in the dosage tank of an automatic injection system.

[0038] The results from the particle size measurements are collected in table I. Table I also supports the finding that the non-diluted suspoemulsion is a very stable formulation, showing no coalescence or heteroflocculation processes over a period of 8 months.

Table I. Particle size distribution of a suspoemulsion, containing flubendazole (Fb), as a function of time.

Preparation	particle size distribution at $t=0$ , (D[3,2] in $\mu\text{m}$ ).	Particle size distribution at 8 months, (D[3,2] in $\mu\text{m}$ ).
10 wt% Fb suspoemulsion	0.99	1.00
Fb powder	1.53	-



**Claims**

1. A method of preparing a veterinary composition comprising a water-insoluble active compound suitable for administering to a target animal through a water distribution system, comprising mixing the active compound with a water-immiscible liquid in such a manner that the mixture of active compound and water-immiscible liquid has a density between 0.85 and 1.2, and suspending said mixture in an aqueous carrier.
2. A method according to claim 1, in which said active compound comprises one or more anthelmintics.
3. A method according to claim 2, in which said anthelmintics comprise a benzimidazole or a pro-benzimidazole.
4. A method according to any one of claims 1-3, in which the active compound and the water-immiscible liquid are used in a weight ratio between 10:90 and 75:25.
5. A method according to any one of claims 1-4, in which either the active compound or the water-immiscible liquid has a lower density than water and the other has a higher density than water.
6. A method according to any one of claims 1-5, in which said mixture or the suspension thereof in the aqueous carrier comprises one or more stabilising agents belonging to the group of emulsifiers, surfactants, thickeners, anti-oxidants and anti-microbials.
7. A method according to any one of claims 1-6, in which said water-immiscible liquid is a vegetable oil.
8. A method according to any one of claims 1-7, in which the average particle size of the active compound is between 1 and 30  $\mu\text{m}$ .
9. A suspoemulsion suitable, optionally after dilution, for administering a veterinary active compound to a target animal through a water distribution system, comprising a

homogeneous suspension in water of a mixture of the active compound and a water-immiscible liquid, said mixture having a density between 0.85 and 1.2.

10. A suspoemulsion according to claim 9, comprising one or more of the following features:
- a) the active compound and the water-immiscible liquid are used in a weight ratio between 10:90 and 75:25;
  - b) the active compound is a benzimidazole anthelmintic;
  - c) the water-immiscible liquid is a vegetable oil;
  - d) the suspoemulsion comprises one or more stabilising agents selected from emulsifiers, surfactants, thickeners, anti-oxidants and anti-microbials;
  - e) the weight ratio between said mixture of active compound a water-immiscible liquid and said water is between 80:20 and 10:90;
  - f) the density of the mixture of active compound and water-immiscible liquid is between 0.95 and 1.05.

**Abstract**

This invention concerns a method for the preparation of a suspoemulsion formulation, which can be easily produced on an industrial scale and which allows the reproducible and effective administration of one or more water-insoluble veterinary drugs through water distribution systems. The water-insoluble veterinary drug, in finely ground form, is dispersed in a water immiscible liquid, followed by homogenisation of this system into a water phase. To facilitate the preparation of a stable formulation, one or more stabilising agents such as emulsifiers, thickeners, anti-oxidants and anti-microbials can be used. The resulting suspoemulsion shows excellent long term storage stability and a good "in use" stability after dilution in a vessel and during all handling and transport in the water distribution system.



10069673. 10/06/02 #4

PTO/SB/01 (10-00)  
Approved for use through 10/31/2002 OMB 051-0032  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

<b>DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</b>  <input type="checkbox"/> Declaration Submitted with Initial Filing <b>OR</b> <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (Surcharge (37 CFR 1.16(e)) required)	Attorney Docket Number	JAB 1525-PCT-USA
	First Named Inventor	Ekhart, Peter Frank et al.
	<b>COMPLETE IF KNOWN</b>	
	Application Number	10/069,673
	Filing Date	February 22, 2002
	Group Art Unit	
Examiner Name		

**As a below named inventor, I hereby declare that:**

My residence, mailing address, and citizenship are as stated below next to my name.  
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**VETERINARY FORMULATION FOR ADMINISTRATION OF A WATER-INSOLUBLE DRUG TO  
A TARGET ANIMAL THROUGH A WATER DISTRIBUTION SYSTEM**

*(Title of the Invention)*

the specification of which

☐ is attached hereto

**OR**

☒ was filed on (MM/DD/YYYY) **February 22, 2002** as United States Application Number 10/069,673 (which is the National Stage of PCT International Application Number **PCT/NL00/00596** and was amended on (MM/DD/YYYY) **February 22, 2002**)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
99202876.1	EP	09/03/1999	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

<b>DECLARATION - Utility or Design Patent Application</b>		
I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.		
Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:		
Application Serial No.	Filing Date	Status
		Patented Patented Patented
I hereby appoint:		
<input checked="" type="checkbox"/> Practitioners at Customer Number <span style="border: 1px solid black; padding: 2px;">000027777</span>		Place Customer Number Bar Code Label Here
AND  <input type="checkbox"/> Practitioner(s) named below:		
Name	Registration Number	
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.		
Address all telephone calls to Ellen Ciambone Coletti at telephone number (732) 524-2359.		
Direct all correspondence to: <input checked="" type="checkbox"/> Customer Number <span style="border: 1px solid black; padding: 2px;">000027777</span> OR <input type="checkbox"/> Correspondence address below		
Name:		
Address:		
Address:		
City:	State:	ZIP
Country	Telephone:	Fax:



Rec'd PCT/PTO 15 OCT 2002

DOCKET NO. JAB-1525 #4

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter Frank Ekhart, et al.

Serial No.: 10/069,673

Art Unit:

Filed : February 22, 2002

Examiner:

For : VETERINARY FORMULATION FOR ADMINISTRATION OF A WATER-INSOLUBLE  
DRUG TO A TARGET ANIMAL THROUGH A WATER DISTRIBUTION SYSTEM

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner for Patents, Washington, DC 20231 on

October 9, 2002

(Date of Deposit)

Ellen Ciambrone Coletti

(Name of applicant, assignee, or Registered Representative)



(Signature)

October 9, 2002

(Date of Signature)

Commissioner For Patents  
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME  
AND AUTHORIZATION TO CHARGE  
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicants petition the Commissioner of Patents and Trademarks to extend the time for response to the Notice of Missing Parts for four months, from June 26, 2002 to October 26, 2002. A Combined Declaration and Power of Attorney responding to the aforesaid Notice to File Missing Parts is being filed concurrently herewith.

Please charge Deposit Account No. 10-0750/JAB-1525/ECC in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,



Ellen Ciambrone Coletti  
Reg. No. 34,140  
Attorney for Applicants

10/18/2002 LLANDGRA 00000051 100750 10069673

02 FC:1254 1440.00 CH

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2359  
DATE: October 9, 2002



DocuPac 15 OCT 2002 547

DOCKET NO. JAB-1525

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter Frank Ekhart et. al.

Serial No.: 10/069,673

Art Unit:

Filed : February 22, 2002

Examiner:

For : VETERINARY FORMULATION FOR ADMINISTRATION OF A WATER-  
INSOLUBLE DRUG TO A TARGET ANIMAL THROUGH A WATER  
DISTRIBUTION SYSTEM

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Box Missing Parts, Commissioner for Patents, Washington, DC 20231 on

October 9, 2002

(Date of Deposit)

Ellen Ciambone Coletti

(Name of applicant, assignee, or Registered Representative)

(Signature)

October 9, 2002

(Date of Signature)

BOX MISSING PARTS  
Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF COMBINED DECLARATION AND POWER OF ATTORNEY

Dear Sir:

Pursuant to Rule 53(f) and Rule 54, please find enclosed a Combined Declaration and Power of Attorney for the application of Peter Frank Ekharat, Mario Van Wandelen, and Jan Mattijs Jetten entitled VETERINARY FORMULATION FOR ADMINISTRATION OF A WATER-INSOLUBLE DRUG TO A TARGET ANIMAL THROUGH A WATER DISTRIBUTION SYSTEM, attorney Docket No. JAB-1525, to complete, pursuant to Rule 51, this application filed on February 22, 2002, by Express Mail pursuant to Rule 10. As required, a copy of the Notice to File Missing Parts of Application is also attached.

Please charge Johnson & Johnson Deposit Account No. 10-0750/JAB-1525/ECC in the amounts of \$130.00 for submission of the Declaration pursuant to Section 1.16(e). The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 10-0750/JAB-1525/ECC. This sheet is submitted in triplicate.

Respectfully submitted,

Ellen Ciambone Coletti  
Reg. No. 34,140  
Attorney for Applicant

10/18/2002 LLANDERA 00000051 100750 10069673

01 FC:1617 130.00 CH

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**NAME OF SOLE OR FIRST INVENTOR:** ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any)) Peter Frank Family Name or Surname Ekhardt

Inventor's Signature [Signature] Date 13-08-2002

Residence: City 1078 VJ Amsterdam State  Country Netherlands Citizenship NL

Mailing Address Nierstraat 61, NL-1078 VJ Amsterdam

City Amsterdam State  ZIP NL-1078 VJ Country The Netherlands

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**NAME OF SECOND INVENTOR:** ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any)) Maria Family Name or Surname Van Wandelen

Inventor's Signature [Signature] Date 13-08-2002

Residence: City NL-3705 PG Zeist State  Country Netherlands Citizenship NL

Mailing Address Rooseveltlaan 14

City Zeist State  ZIP NL-3705 PG Country The Netherlands

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**NAME OF THIRD INVENTOR:** ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any)) Jan Matthijs Family Name or Surname Jetten

Inventor's Signature [Signature] Date August 13, 2002

Residence: City NL-3701 JL Zeist State  Country Netherlands Citizenship NL

Mailing Address Costerlaan 3b

City Zeist State  ZIP NL-3701 JL Country The Netherlands


NLX

NLX

NLX



United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) \_\_\_\_\_ of **Assignment** \_\_\_\_\_ were not  
present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not  
present  
for scanning. (Document title)

☐ *Scanned copy is best available.*